Royalty Pharma filed the largest IPO of 2020 in the second quarter, emerging into a public market amid the COVID-19 pandemic with innovative funding strategies for pharmaceutical companies.
Funding key research and development and commercial activities are a high priority as companies across the pharmaceutical and life sciences industry look to emerge stronger from the COVID crisis.